MacroGenics, Inc.

MacroGenics, Inc.

2.00
CHF
-0.49
(-19.81%)
-1.32EPS
162.06MMarket Cap
Feb 25Next Earn

Total Valuation

CHF

As of June 30, 2026, MacroGenics, Inc. carries a market capitalization of 162.06M, placing it among publicly traded companies globally. Its enterprise value stands at 50.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap162.06M
Enterprise Value50.40M

Important Dates

MacroGenics, Inc.'s next confirmed earnings release is scheduled for February 25, 2027.

Earnings Date2/25/2027

Share Statistics

As of June 30, 2026, MacroGenics, Inc. has 63.44M shares outstanding.

Shares Outstanding63.44M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 1.19, and the price-to-book ratio stands at 4.68.

PS Ratio1.19
PB Ratio4.68
P/TBV Ratio4.68
P/FCF Ratio-3.05
P/OCF Ratio-3.14

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 0.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 50.40M versus a market cap of 162.06M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.37

Financial Position

As of June 30, 2026, MacroGenics, Inc. maintains a current ratio of 2.96, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 81.85, indicating elevated leverage, while an interest coverage ratio of -2.06 demonstrates limited ability to service its debt obligations.

Current Ratio2.96
Quick Ratio2.92
Debt / Equity81.85
Debt / EBITDA-1.01
Interest Coverage-2.06

Financial Efficiency

CHF

Over the twelve months ended June 30, 2026, MacroGenics, Inc. posted a negative return on equity (ROE) of -32.61, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.94, reflecting losses generated across the asset base. The company generates approximately 444,102.56 in revenue per employee across its workforce of 305.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-32.61
Return on Assets (ROA)-4.94
Revenue Per Employee444,102.56
Employee Count305.00

Taxes

CHF

Over the twelve months ended June 30, 2026, MacroGenics, Inc. recorded an income tax benefit of -627,683.91 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -84.44M and -11.79M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-627,683.91

Income Statement

CHF

Over the twelve months ended June 30, 2026, MacroGenics, Inc. generated 135.45M in revenue and converted that into -11.79M in net income, yielding earnings per share of -1.32. EBITDA reached -28.16M, while operating income came in at -32.92M.

Revenue135.45M
Operating Income-32.92M
Pretax Income-84.44M
Net Income-11.79M
EBITDA-28.16M
EBIT-32.92M
Earnings Per Share (EPS)-1.32

Balance Sheet

CHF

As of June 30, 2026, MacroGenics, Inc. holds 140.00M in cash and equivalents against 28.35M in total debt, resulting in a net debt position of -92.02M. Total book value stands at 34.63M, with working capital of 171.96M providing operational flexibility.

Cash & Cash Equivalents140.00M
Total Debt28.35M
Net Debt-92.02M
Equity (Book Value)34.63M
Book Value Per Share0.55
Working Capital171.96M

Cash Flow

CHF

MacroGenics, Inc. produced -51.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.47M in capital expenditures, free cash flow totaled -52.95M - equivalent to -0.84 per share.

Operating Cash Flow-51.48M
Capital Expenditures-1.47M
Free Cash Flow-52.95M
FCF Per Share-0.84

Margins

These figures cover the twelve months ended June 30, 2026. The operating margin of -24.30 and net profit margin of -8.70 provide insight into operational efficiency.

Operating Margin-24.30
Pretax Margin-62.34
Profit Margin-8.70
EBITDA Margin-20.79

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -32.77: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -29.92, meaning MacroGenics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-29.92
FCF Yield-32.77

Scores

As of June 30, 2026, MacroGenics, Inc. has an Altman Z-Score of -3.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-3.88